san jose collage
San Jose
Serving San Jose, California (Santa Clara County)Vol. 1, No. 23
Business

J&J will pay $2.2 billion upfront for a startup whose eye shot beat South San Francisco-made Vabysmo on some measures in an early trial

The deal for Austin-based Ollin Biosciences could reach about $3.3 billion with milestone payments.  Blackstone will put up $750 million to pay for final-stage testing in wet macular degeneration and diabetic eye swelling.

ShareFacebookXEmail
A doctor in a blue surgical gown, mask and gloves looks through a white surgical microscope while holding a thin instrument near a patient’s eye, which is lit by the microscope’s light.
A doctor gives an injection into a patient’s eye under a microscope, the way drugs like Vabysmo are given for wet macular degeneration. — Photo:  Zkalila1998 via Wikimedia Commons (CC BY-SA 4.0)

Johnson & Johnson has agreed to buy Ollin Biosciences, a young Austin, Texas, drug developer, for $2.2 billion upfront, plus up to about $1.125 billion more if the company’s lead drug hits regulatory and sales goals, J&J announced Monday.  That puts the potential total at about $3.3 billion.  The deal is expected to close before the end of 2026, pending government approvals and other usual conditions.

The prize is OLN324, an experimental shot for wet age-related macular degeneration and diabetic macular edema.  Both conditions damage the retina, the light-sensing layer at the back of the eye, and together they affect more than 40 million people worldwide, according to J&J.  They are the leading causes of vision loss in older and working-age people, respectively, Ollin says.

What it means

For patients, nothing changes yet.  OLN324 still has to succeed in final-stage Phase 3 trials and win FDA approval.  If it does, it would compete with Vabysmo, the eye drug from South San Francisco’s Genentech, which targets the same two proteins.  J&J’s Kip Connor said the data suggest OLN324 “could deliver more effective reduction of retinal fluid and allow more time between treatments.”

How the drug works

In both diseases, fluid leaks into the retina and blurs vision.  OLN324 is a bispecific antibody, meaning one lab-made molecule blocks two targets:  VEGF and angiopoietin-2, proteins that drive the leaky blood vessels.  Ollin says its version blocks angiopoietin-2 more strongly than Vabysmo and is smaller, so more of it can be given in each dose.

In Ollin’s Phase 1b JADE study of 164 U.S. patients, all received three monthly doses of OLN324 or Vabysmo and were then followed for 12 weeks.  In diabetic macular edema, OLN324 dried the retina faster and more, with fewer patients needing an extra shot (7% vs. 11%).  In wet macular degeneration, drying was about the same, and vision gains were slightly better, about 2.2 more letters on an eye chart, but not proven to be a real difference.  There were no cases of eye inflammation with OLN324 and one with Vabysmo, Ollin reported in March.  These are company-reported results from a small early study.

The deal terms

  • Price:  $2.2 billion upfront and up to about $1.125 billion in milestones.  Ollin is private, so there is no public share price or premium.  J&J did not say whether it is paying in cash or stock.
  • Blackstone:  Blackstone Life Sciences, a private investment firm, will pay J&J $750 million over several years to fully fund OLN324’s Phase 3 trials, in return for milestone payments and royalties in the single digits as a percentage of sales.
  • Jobs:  J&J did not say how many people Ollin employs or whether any jobs will be cut.
  • Accounting:  J&J said it will explain how it will book the deal on or before closing.

Who they are

Ollin launched in September 2025 with $100 million from investors led by ARCH Venture Partners, Mubadala Capital and Monograph Capital, with co-founder Jason Ehrlich as CEO.  It acquires promising eye drugs and develops them; it is developing OLN324 with China’s Innovent Biologics.  Its second drug, OLN102, aims at thyroid eye disease, which can make the eyes bulge, and has not yet been tested in people.  J&J, based in New Brunswick, N.J., already sells vision care products, and the deal is its push to build up eye medicines.

Source:  Johnson & Johnson, “Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology,” Nov. 16, 2026; Ollin Biosciences, launch announcement, Sept. 17, 2025; Ollin Biosciences, final JADE study data, March 30, 2026; Genentech press releases.

Drafted by AI from the linked public source. Approved by a Daily News Editor.

Sources and documents